<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="54532">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02396225</url>
  </required_header>
  <id_info>
    <org_study_id>M-2013-242-13</org_study_id>
    <nct_id>NCT02396225</nct_id>
  </id_info>
  <brief_title>Concentrations of Voriconazole in Blood and BAL-fluid After Inhalation and Oral Administration</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Concentrations of voriconazole in pulmonary epithelial lining fluid and in serum are
      compared after inhalation of 40 mg voriconazole b.i.d. for two days or oral intake of
      voriconazole tablets 400 mg bid for 1 day followed by 200 mg b.i.d. for one day,
      respectively.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Voriconazole concentration in serum</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Voriconazole concentration in lunge epithelial lining fluid</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Invasive Aspergillosis</condition>
  <arm_group>
    <arm_group_label>Inhaled voriconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 patients inhale voriconazole 40 mg b.i.d for two days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Voriconazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 patients ingest voriconazole tablets 400 mg b.i.d for one day followed by 200 mg b.i.d for one day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voriconazole</intervention_name>
    <arm_group_label>Inhaled voriconazole</arm_group_label>
    <arm_group_label>Oral Voriconazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Planned bronchoscopy in relation to work-up after hemoptysis or other symptom leading
             to bronchoscopy

          -  Informed written consent

          -  Performance status 0-1

          -  Ct scan of thorax without suspicion of malignancy

          -  Weight t ≥ 60 og ≤ 130 kg

          -  Male gender or female gender in postmenopausal state defined by amenorrhea in more
             than 12 months.

        Exclusion Criteria:

          -  Voriconazole treatment up to one week before inclusion

          -  Se-creatinin≥ 100 uM

          -  ALAT ≥ 70 U/l

          -  QT-interval &gt; 480 ms

          -  Allergic reaction to voriconazole or constituents in Vfend

          -  Allergic reaction to other azoles

          -  Ischemic Heart disease, Heart failure or uncontrolled hypertension

          -  Treatment with statins or omeprazole, which cannot be paused for three days during
             voriconazole exposure

          -  Treatment with Efavirenz, rifabutin, ritonavir, everolimus, methadon, alfentanil,
             fentanyl, sufentanil, oxycodone, hydrocodone, fluconazole, aztemizol, cisaprid,
             pimozid, quinidine, terfenadine, carbamazepine, phenobarbital, mephobarbital,
             ergotamine, dihydroergotamine, rifampicine, st. johns worth, everolimus, phenytoin,
             warfarin, phenprocoumon, acenocoumarol, benzodiazepines as midazolam, triazolam,
             alprazolam, sirolimus, cyclosporine, tacrolimus, ibuprofen, diclofenac,tolbutamide,
             glipizide, vincristine, vinblastine or other vinca alkaloids, HIV-protease Inhibitors
             e.g. saquinavir, amprenavir and nelfinavir, delavirdine, nivrapine and other
             non-nocleaoside revers transcriptase inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Charlotte Andersen, MD PhD</last_name>
    <email>cua@farm.au.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ole Hilberg, MDSC</last_name>
    <email>olehilbe@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Andersen, MD Phd</last_name>
      <email>cua@farm.au.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>December 22, 2016</lastchanged_date>
  <firstreceived_date>March 18, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>voriconazole</keyword>
  <keyword>inhalation</keyword>
  <keyword>aerosol</keyword>
  <keyword>epithelial lining fluid</keyword>
  <keyword>concentration</keyword>
  <keyword>pharmacokinetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspergillosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Voriconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
